NOVEMBER 20218 MANUFACTURING TECHNOLOGY INSIGHTSIN MY OPINIONBy Gurinder Kaur, VP, Global Operations IT, AstraZenecaAt AstraZeneca, we push the boundaries of science to deliver life-changing medicines. Our Global Operations represents a significant component of our global footprint, with 26 operations sites in 16 countries and more than 14,000 people. As our portfolio of medicines continues to evolve, as we introduce new medicines, and as patient demand grows, we have not only an opportunity but an obligation to transform our operations and ensure that, through constant innovation, our network is fit for the future to ensure our commitment to patients.In support of this, we are focused on accelerating our digital transformation across all aspects of our operations, including accelerating plans to create a network of smart factories. The changing portfolio of our medicines and new patient expectations will require the introduction of new manufacturing processes and technologies, and therefore we are transforming our company to automate, accelerate and increase the efficiency and effectiveness of our operations.Digitization and the development of smart factories enable us to replace slow, disconnected, and labor-intensive processes with faster, smarter, more transparent ones. In manufacturing, that involves automating processes and embracing robotics to build smart factories. The use of advanced predictive analytics at our Biologics site in the US is providing foresight of variability, and improving batch yield performance. In our complex global supply chains, the use of real-time data and artificial intelligence helps ensure the right goods, materials and equipment are in the right place at the right time.Accelerating Smart Factories to Support Our Commitment to Patients
< Page 7 | Page 9 >